PepGen (PEPG) Competitors $1.32 +0.07 (+5.60%) Closing price 04:00 PM EasternExtended Trading$1.33 +0.01 (+0.76%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PEPG vs. ACTU, NKTX, NVCT, CYBN, BIOA, GLSI, CRDF, DERM, CLLS, and MEIPShould you be buying PepGen stock or one of its competitors? The main competitors of PepGen include Actuate Therapeutics (ACTU), Nkarta (NKTX), Nuvectis Pharma (NVCT), Cybin (CYBN), BioAge Labs (BIOA), Greenwich LifeSciences (GLSI), Cardiff Oncology (CRDF), Journey Medical (DERM), Cellectis (CLLS), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical products" industry. PepGen vs. Its Competitors Actuate Therapeutics Nkarta Nuvectis Pharma Cybin BioAge Labs Greenwich LifeSciences Cardiff Oncology Journey Medical Cellectis MEI Pharma Actuate Therapeutics (NASDAQ:ACTU) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability. Do analysts recommend ACTU or PEPG? Actuate Therapeutics currently has a consensus price target of $20.50, indicating a potential upside of 145.22%. PepGen has a consensus price target of $7.67, indicating a potential upside of 480.81%. Given PepGen's higher possible upside, analysts plainly believe PepGen is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00PepGen 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do insiders and institutionals believe in ACTU or PEPG? 58.0% of PepGen shares are held by institutional investors. 69.3% of Actuate Therapeutics shares are held by company insiders. Comparatively, 5.2% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher valuation & earnings, ACTU or PEPG? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$27.28MN/AN/APepGenN/AN/A-$89.98M-$2.96-0.45 Is ACTU or PEPG more profitable? PepGen's return on equity of -92.51% beat Actuate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A -19,736.59% -281.83% PepGen N/A -92.51%-70.39% Does the media favor ACTU or PEPG? In the previous week, Actuate Therapeutics had 13 more articles in the media than PepGen. MarketBeat recorded 14 mentions for Actuate Therapeutics and 1 mentions for PepGen. Actuate Therapeutics' average media sentiment score of 0.07 beat PepGen's score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryActuate Therapeutics beats PepGen on 5 of the 9 factors compared between the two stocks. Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEPG vs. The Competition Export to ExcelMetricPepGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.30M$3.09B$5.82B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-0.4521.1431.1525.96Price / SalesN/A397.29474.77122.97Price / CashN/A43.0937.1558.38Price / Book0.618.079.116.39Net Income-$89.98M-$54.72M$3.26B$265.56M7 Day Performance2.33%2.62%2.12%1.98%1 Month Performance-5.71%7.64%5.13%1.33%1 Year Performance-86.41%13.11%31.25%21.15% PepGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PEPGPepGen2.7442 of 5 stars$1.32+5.6%$7.67+480.8%-87.3%$43.30MN/A-0.4530ACTUActuate TherapeuticsN/A$8.25+1.6%$20.50+148.5%-10.9%$166.22MN/A0.0010News CoverageAnalyst RevisionNKTXNkarta2.0708 of 5 stars$2.35+0.9%$13.60+478.7%-56.9%$165.49MN/A-1.59140NVCTNuvectis Pharma3.8378 of 5 stars$6.45+0.3%$15.33+137.7%-11.3%$163.69MN/A-5.518Positive NewsCYBNCybin2.5036 of 5 stars$6.92-2.0%$85.00+1,128.3%N/A$163.24MN/A-1.5850News CoverageAnalyst RevisionBIOABioAge LabsN/A$4.52-0.7%N/AN/A$163.12M$3.86M0.00N/AGLSIGreenwich LifeSciences1.4633 of 5 stars$12.01-1.3%$39.00+224.7%-19.9%$162.69MN/A-8.833Trending NewsAnalyst ForecastAnalyst RevisionCRDFCardiff Oncology1.6395 of 5 stars$2.43-0.4%$10.10+315.6%-3.0%$162.32M$680K-2.7920DERMJourney Medical1.6736 of 5 stars$7.00+0.7%$10.83+54.8%+60.9%$161.91M$56.13M-18.4290CLLSCellectis3.3705 of 5 stars$2.90+1.8%$4.00+37.9%+17.6%$158.41M$49.22M-3.54290Positive NewsShort Interest ↓MEIPMEI Pharma1.3625 of 5 stars$4.88-0.2%N/A+47.1%$158.28M$65.30M-1.03100 Related Companies and Tools Related Companies Actuate Therapeutics Alternatives Nkarta Alternatives Nuvectis Pharma Alternatives Cybin Alternatives BioAge Labs Alternatives Greenwich LifeSciences Alternatives Cardiff Oncology Alternatives Journey Medical Alternatives Cellectis Alternatives MEI Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PEPG) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access